Sierra Oncology, Inc. announced that it has closed its previously announced underwritten public offering, with gross proceeds to Sierra Oncology of $103 million. Following the closing of this offering, Mr. Robert Pelzer, who has served as a member of the company's Board of Directors since May 2015, has been appointed as the Chairman of the Board of Directors. The company also appointed Dr. Gaurav Aggarwal, Dr. Josh Richardson, Dr. Mona Ashiya and Dr. Andrew Sinclair to the Board of Directors, each of whom are affiliated with investors in the offering. In addition, Mr. Donald Parfet, Dr. Daniel Estes, Dr. Nicole Onetto and Mr. Tran Nguyen have resigned from the Board of Directors. The foregoing appointments and resignations were effective as of November 22, 2019. Robert Pelzer has served as a member of its Board of Directors since May 2015. From September 2008 to March 2013, Mr. Pelzer served as the President of Novartis Corporation, a pharmaceutical company. Gaurav Aggarwal, M.D., has served as a Managing Director of Vivo Capital LLC, since October 2016, where he focuses on investments in life sciences companies. Dr. Aggarwal previously served as the Chief Business Officer of Ocera Therapeutics, as Managing Director of Investor Growth Capital, and as a General Partner at Panorama Capital, L.P. Josh Richardson, M.D., has served as Managing Director of Longitude Capital since February 2016 where he focuses on investments in biotechnology companies. From September 2014 to February 2016, Dr. Richardson served as a Public Equities Analyst at HealthCor Management where he managed small and mid-cap biotechnology investments. Mona Ashiya, Ph.D, is currently a Partner at OrbiMed Advisors, LLC. She has been at OrbiMed since 2010 where she has been involved with a number of investments in public and private biotech companies. Andrew Sinclair, Ph.D., has served in various positions since November 2008 at Abingworth LLP, where he currently serves as a Partner and Portfolio Manager. Dr. Sinclair currently serves on the Boards of Directors of Soleno Therapeutics, Inc. and Verona Pharma plc. Dr. Sinclair is a member of the Institute of Chartered Accountants in England and Wales.